Lino Gandola

Keyron is a UK- and US-based, preclinical-stage medical device and technology platform company aimed at a highly effective treatment of metabolic diseases. Keyron’s patented ForePass® is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA. Keyron is currently fundraising for a $7.5m Series A investment round. Please contact our CEO, Carl D. Francis (c.francis@keyron.com) for investment enquiries. Disclaimer: This is not a solicitation of investment.

Welcome to BCHAR on LinkedIn! BCHAR offers a turn-key biochar production system that handles the entire process — from biomass input to biochar output — all from one supplier. Our solution integrates fully automated hardware with built-in MRV software, providing unmatched transparency for carbon credit generation. With its automated design, BCHAR makes turning waste into value as simple and efficient as possible.

Currently building the worlds first fully reusable medium-lift launch vehicle, Razor Crest Mk-1. The company is founded to significantly reduce space transportation costs, enable quick scientific growth, and catalyze civilizational progress.

Signatur Biosciences makes precision diagnostics more accessible, starting by bringing breast cancer testing within reach for women around the world. Traditional tests used to guide therapy are slow and expensive due to their reliance on complex, centralized facilities. Our tests are designed to seamlessly integrate with standard instruments and workflows already in place in every clinical lab. Our assays empower local labs to deliver results in hours instead of weeks and at a fraction of the cost, significantly increasing accessibility, including for underserved patient populations. Signatur Biosciences is a spinout backed by YCombinator, founded by bioengineers from Imperial College and Oxford University.

We are an Indian space-tech company specialising in green propulsion systems. Founded by IIT Bombay alumni, the company provides full-stack manoeuvrability solutions for modern satellite missions and kick-stages of launch vehicles. The rapid increase in satellite launches is significantly raising the risk of in-orbit collisions, making reliable propulsion essential for maneuvering and end-of-life de-orbiting. However, existing systems rely on toxic fuels like hydrazine, which are expensive to handle, require complex ground infrastructure and create operational challenges. Manastu addresses this with a hydrogen-peroxide based green propulsion system that is safer, cost-efficient and designed for rapid integration, enabling agile maneuvering, collision avoidance and sustainable satellite operations at scale. Manastu Space combines flight heritage, early international contracts, and a globally relevant, scalable propulsion solution, positioning it strongly for export readiness and rapid expansion across key space markets. From space-qualified hardware on ISRO missions to strategic defense collaborations, Manastu Space is committed to safe satellite missions while reducing the environmental footprint of space exploration. With a team of 100+ experts and a legacy of innovation in high temperature catalyst, green propellant and advanced combustion chamber, spanning 9 years, we are propelling the next generation of sustainable space missions.

Keyron is a UK- and US-based, preclinical-stage medical device and technology platform company aimed at a highly effective treatment of metabolic diseases. Keyron’s patented ForePass® is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA. Keyron is currently fundraising for a $7.5m Series A investment round. Please contact our CEO, Carl D. Francis (c.francis@keyron.com) for investment enquiries. Disclaimer: This is not a solicitation of investment.

Welcome to BCHAR on LinkedIn! BCHAR offers a turn-key biochar production system that handles the entire process — from biomass input to biochar output — all from one supplier. Our solution integrates fully automated hardware with built-in MRV software, providing unmatched transparency for carbon credit generation. With its automated design, BCHAR makes turning waste into value as simple and efficient as possible.

Currently building the worlds first fully reusable medium-lift launch vehicle, Razor Crest Mk-1. The company is founded to significantly reduce space transportation costs, enable quick scientific growth, and catalyze civilizational progress.

Signatur Biosciences makes precision diagnostics more accessible, starting by bringing breast cancer testing within reach for women around the world. Traditional tests used to guide therapy are slow and expensive due to their reliance on complex, centralized facilities. Our tests are designed to seamlessly integrate with standard instruments and workflows already in place in every clinical lab. Our assays empower local labs to deliver results in hours instead of weeks and at a fraction of the cost, significantly increasing accessibility, including for underserved patient populations. Signatur Biosciences is a spinout backed by YCombinator, founded by bioengineers from Imperial College and Oxford University.

An early-stage venture capital with a focus on companies building for global markets.